Phase Ib/II Study Of Revumenib As Monotherapy Or In Combination With Jak Inhibitors In Patients With Myelofibrosis

Summary

This is a Phase Ib/II 2 study investigating the safety and efficacy of revumenib in two cohorts of participants with myelofibrosis. COHORT-1 will investigate the safety of revumenib as monotherapy in participants with myelofibrosis previously treated with a JAK inhibitor. Following confirmation of safety in COHORT-1, the study will proceed with enrollment in COHORT-2, which will evaluate the efficacy and safety of revumenib in combination with a JAK inhibitor.

Description

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Revumenib

  Dose Level 1: Revumenib 160mg twice daily or 110mg twice daily Dose Level 2: Revumenib 270mg twice daily or 160mg twice daily

• Drug
  Ruxolitinib

  Part of routine care. Participants to continue on dosage as prescribed by provider, 5 to 20 mg BID

• Drug
  FEDRATINIB

  Part of routine care. Participants to continue on dosage as prescribed by provider, 100 mg to 400 mg daily.

• Drug
  Momelotinib

  Part of routine care. Participants to continue on dosage as prescribed by provider, 100 mg to 200 mg daily.

Location